A live attenuated strain of Yersinia pestis KIM as a vaccine against plague

Wei Sun, David Six, Xiaoying Kuang, Kenneth L. Roland, Christian R H Raetz, Roy Curtiss

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Yersinia pestis, the causative agent of plague, is a potential weapon of bioterrorism. Y. pestis evades the innate immune system by synthesizing tetra-acylated lipid A with poor Toll-like receptor 4 (TLR4)-stimulating activity at 37°C, whereas hexa-acylated lipid A, a potent TLR4 agonist, is made at lower temperatures. Synthesis of Escherichia coli LpxL, which transfers the secondary laurate chain to the 2'-position of lipid A, in Y. pestis results in production of hexa-acylated lipid A at 37°C, leading to significant attenuation of virulence. Previously, we described a Y. pestis vaccine strain in which crp expression is under the control of the arabinose-regulated araC PBAD promoter, resulting in a 4-5 log reduction in virulence. To reduce the virulence of the crp promoter mutant further, we introduced E. coli lpxL into the Y. pestis chromosome. The χ10030(pCD1Ap) (ΔlpxP32::PlpxL lpxL ΔPcrp21::TT araC PBAD crp) construct likewise produced hexa-acylated lipid A at 37°C and was significantly more attenuated than strains harboring each individual mutation. The LD50 of the mutant in mice, when administered subcutaneously or intranasally was >107-times and >104-times greater than wild type, respectively. Mice immunized subcutaneously with a single dose of the mutant were completely protected against a subcutaneous challenge of 3.6×107 wild-type Y. pestis and significantly protected (80% survival) against a pulmonary challenge of 1.2×104 live cells. Intranasal immunization also provided significant protection against challenges by both routes. This mutant is an immunogenic, highly attenuated live Y. pestis construct that merits further development as a vaccine candidate.

Original languageEnglish (US)
Pages (from-to)2986-2998
Number of pages13
JournalVaccine
Volume29
Issue number16
DOIs
StatePublished - Apr 5 2011

Fingerprint

Plague Vaccine
Yersinia pestis
plague
Lipid A
vaccines
Virulence
Toll-Like Receptor 4
mutants
virulence
Vaccines
Laurates
Escherichia coli
Bioterrorism
promoter regions
Arabinose
Weapons
Plague
bioterrorism
Y Chromosome
Lethal Dose 50

Keywords

  • Lipid A
  • Plague vaccine
  • Regulated delayed attenuation
  • Yersinia pestis

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Sun, W., Six, D., Kuang, X., Roland, K. L., Raetz, C. R. H., & Curtiss, R. (2011). A live attenuated strain of Yersinia pestis KIM as a vaccine against plague. Vaccine, 29(16), 2986-2998. https://doi.org/10.1016/j.vaccine.2011.01.099

A live attenuated strain of Yersinia pestis KIM as a vaccine against plague. / Sun, Wei; Six, David; Kuang, Xiaoying; Roland, Kenneth L.; Raetz, Christian R H; Curtiss, Roy.

In: Vaccine, Vol. 29, No. 16, 05.04.2011, p. 2986-2998.

Research output: Contribution to journalArticle

Sun, W, Six, D, Kuang, X, Roland, KL, Raetz, CRH & Curtiss, R 2011, 'A live attenuated strain of Yersinia pestis KIM as a vaccine against plague', Vaccine, vol. 29, no. 16, pp. 2986-2998. https://doi.org/10.1016/j.vaccine.2011.01.099
Sun W, Six D, Kuang X, Roland KL, Raetz CRH, Curtiss R. A live attenuated strain of Yersinia pestis KIM as a vaccine against plague. Vaccine. 2011 Apr 5;29(16):2986-2998. https://doi.org/10.1016/j.vaccine.2011.01.099
Sun, Wei ; Six, David ; Kuang, Xiaoying ; Roland, Kenneth L. ; Raetz, Christian R H ; Curtiss, Roy. / A live attenuated strain of Yersinia pestis KIM as a vaccine against plague. In: Vaccine. 2011 ; Vol. 29, No. 16. pp. 2986-2998.
@article{2a529a9647c2492d9906ad787b2777a3,
title = "A live attenuated strain of Yersinia pestis KIM as a vaccine against plague",
abstract = "Yersinia pestis, the causative agent of plague, is a potential weapon of bioterrorism. Y. pestis evades the innate immune system by synthesizing tetra-acylated lipid A with poor Toll-like receptor 4 (TLR4)-stimulating activity at 37°C, whereas hexa-acylated lipid A, a potent TLR4 agonist, is made at lower temperatures. Synthesis of Escherichia coli LpxL, which transfers the secondary laurate chain to the 2'-position of lipid A, in Y. pestis results in production of hexa-acylated lipid A at 37°C, leading to significant attenuation of virulence. Previously, we described a Y. pestis vaccine strain in which crp expression is under the control of the arabinose-regulated araC PBAD promoter, resulting in a 4-5 log reduction in virulence. To reduce the virulence of the crp promoter mutant further, we introduced E. coli lpxL into the Y. pestis chromosome. The χ10030(pCD1Ap) (ΔlpxP32::PlpxL lpxL ΔPcrp21::TT araC PBAD crp) construct likewise produced hexa-acylated lipid A at 37°C and was significantly more attenuated than strains harboring each individual mutation. The LD50 of the mutant in mice, when administered subcutaneously or intranasally was >107-times and >104-times greater than wild type, respectively. Mice immunized subcutaneously with a single dose of the mutant were completely protected against a subcutaneous challenge of 3.6×107 wild-type Y. pestis and significantly protected (80{\%} survival) against a pulmonary challenge of 1.2×104 live cells. Intranasal immunization also provided significant protection against challenges by both routes. This mutant is an immunogenic, highly attenuated live Y. pestis construct that merits further development as a vaccine candidate.",
keywords = "Lipid A, Plague vaccine, Regulated delayed attenuation, Yersinia pestis",
author = "Wei Sun and David Six and Xiaoying Kuang and Roland, {Kenneth L.} and Raetz, {Christian R H} and Roy Curtiss",
year = "2011",
month = "4",
day = "5",
doi = "10.1016/j.vaccine.2011.01.099",
language = "English (US)",
volume = "29",
pages = "2986--2998",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "16",

}

TY - JOUR

T1 - A live attenuated strain of Yersinia pestis KIM as a vaccine against plague

AU - Sun, Wei

AU - Six, David

AU - Kuang, Xiaoying

AU - Roland, Kenneth L.

AU - Raetz, Christian R H

AU - Curtiss, Roy

PY - 2011/4/5

Y1 - 2011/4/5

N2 - Yersinia pestis, the causative agent of plague, is a potential weapon of bioterrorism. Y. pestis evades the innate immune system by synthesizing tetra-acylated lipid A with poor Toll-like receptor 4 (TLR4)-stimulating activity at 37°C, whereas hexa-acylated lipid A, a potent TLR4 agonist, is made at lower temperatures. Synthesis of Escherichia coli LpxL, which transfers the secondary laurate chain to the 2'-position of lipid A, in Y. pestis results in production of hexa-acylated lipid A at 37°C, leading to significant attenuation of virulence. Previously, we described a Y. pestis vaccine strain in which crp expression is under the control of the arabinose-regulated araC PBAD promoter, resulting in a 4-5 log reduction in virulence. To reduce the virulence of the crp promoter mutant further, we introduced E. coli lpxL into the Y. pestis chromosome. The χ10030(pCD1Ap) (ΔlpxP32::PlpxL lpxL ΔPcrp21::TT araC PBAD crp) construct likewise produced hexa-acylated lipid A at 37°C and was significantly more attenuated than strains harboring each individual mutation. The LD50 of the mutant in mice, when administered subcutaneously or intranasally was >107-times and >104-times greater than wild type, respectively. Mice immunized subcutaneously with a single dose of the mutant were completely protected against a subcutaneous challenge of 3.6×107 wild-type Y. pestis and significantly protected (80% survival) against a pulmonary challenge of 1.2×104 live cells. Intranasal immunization also provided significant protection against challenges by both routes. This mutant is an immunogenic, highly attenuated live Y. pestis construct that merits further development as a vaccine candidate.

AB - Yersinia pestis, the causative agent of plague, is a potential weapon of bioterrorism. Y. pestis evades the innate immune system by synthesizing tetra-acylated lipid A with poor Toll-like receptor 4 (TLR4)-stimulating activity at 37°C, whereas hexa-acylated lipid A, a potent TLR4 agonist, is made at lower temperatures. Synthesis of Escherichia coli LpxL, which transfers the secondary laurate chain to the 2'-position of lipid A, in Y. pestis results in production of hexa-acylated lipid A at 37°C, leading to significant attenuation of virulence. Previously, we described a Y. pestis vaccine strain in which crp expression is under the control of the arabinose-regulated araC PBAD promoter, resulting in a 4-5 log reduction in virulence. To reduce the virulence of the crp promoter mutant further, we introduced E. coli lpxL into the Y. pestis chromosome. The χ10030(pCD1Ap) (ΔlpxP32::PlpxL lpxL ΔPcrp21::TT araC PBAD crp) construct likewise produced hexa-acylated lipid A at 37°C and was significantly more attenuated than strains harboring each individual mutation. The LD50 of the mutant in mice, when administered subcutaneously or intranasally was >107-times and >104-times greater than wild type, respectively. Mice immunized subcutaneously with a single dose of the mutant were completely protected against a subcutaneous challenge of 3.6×107 wild-type Y. pestis and significantly protected (80% survival) against a pulmonary challenge of 1.2×104 live cells. Intranasal immunization also provided significant protection against challenges by both routes. This mutant is an immunogenic, highly attenuated live Y. pestis construct that merits further development as a vaccine candidate.

KW - Lipid A

KW - Plague vaccine

KW - Regulated delayed attenuation

KW - Yersinia pestis

UR - http://www.scopus.com/inward/record.url?scp=79953231573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953231573&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.01.099

DO - 10.1016/j.vaccine.2011.01.099

M3 - Article

VL - 29

SP - 2986

EP - 2998

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 16

ER -